A clinical trial has found no evidence of a link between adenotonsillectomies and unwanted weight gain in children. A recent ...

This weight-loss drug, designed for obese patients, significantly reduces breathing disruptions and offers a new treatment ...

According to a Canadian study, these stories could also become excellent educational aids for teaching children the ...

Indianapolis: Eli Lilly and Company has announced the U.S. Food and Drug Administration (FDA) has approved Zepbound ...

A vote on a temporary spending bill to fund the government past Friday's midnight government funding deadline passed 366 to ...

An outbreak of salmonella linked to cucumbers has now been tied to 100 known cases of the illness across 23 states, the U.S.

YolTech Therapeutics today announced updated data from its ongoing Phase I/IIa clinical trial of YOLT-201, a first-in-class CRISPR/Cas9-based in vivo gene-editing therapy for ATTR amyloidosis. The ...

Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, ...

For years after Dr. Lome began his cardiology practice, he was suffering from hypertension, high cholesterol levels and sleep ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

T he weight-loss drug Zepbound (tirzepatide) now has another major benefit: on Dec. 20, it became the first drug approved by ...

The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...